Publications

Publications

Metastasis as a therapeutic target in prostate cancer: a conceptual framework

By:
Contributors: Andries Zijlstra Research Group, Katie Hebron, John D. Lewis Research Group, David Bond, PhD, Konstantin Stoletov, PhD, Srijan Raha
Am J Clin Exp Urol. 2014 Apr;2(1):45-56.

Abstract

Metastasis is the main cause of prostate cancer-associated deaths. While significant progerss has been made in the treatment of primary tumors, efficent therapies that target the metastatic spread of prostate cancer are far from clinical reality. To efficiently treat cancer we need be able to impede its spread. Unfortunately, the majority of current therapeutics approved to treat metastatic cancer were originally selected based on their ability to inhibit primary tumor growth. This inherent flaw precluded these therapies from efficiently targeting the development of secondary metastatic lesions, a process that is distinct from that of primary tumor progression. In this review we will summarize the conceptual, cellular and molecular targets that should be considered to design effective anti-metastatic therapies.

 

PubMed

Download PDF

 

Thank you for attending the 2023 APCaRI Fall Symposium!

The 2023 APCaRI Fall Symposium, held September 22nd and 23rd, was a huge success! Thank you all for joining us in beautiful Banff, Alberta.  The keynote and APCaRI member speakers gave inspiring and informative talks.

We are especially appreciative of the participants representing patient advocacy groups, urologists, oncologists, funders, clinicians, trainees, and researchers who engaged in lively and productive conversation!

Thank you again to our sponsors Astellas, AstraZeneca, Bayer, Janssen, Merck, and Pfizer who made this symposium possible.

APCaRI looks forward to seeing all of you again soon!

 

- Max Uhlich